Key result
Monocrotaline rat model provides an in vivo protocol to evaluate therapies for pulmonary hypertension.
Why the study?
Pulmonary arterial hypertension is a debilitating and often fatal disease characterized by progressively increased pulmonary vascular resistance leading to right ventricular failure, requiring an in vivo model to assess the effects of antihypertensive agents.
Monocrotaline rat model enables preclinical testing of PAH agents on PAP and RVH; leaves open clinical translation.
Pulmonary arterial hypertension (PAH) is a debilitating and often fatal disease characterized by a progressive increase in pulmonary vascular resistance that leads to right ventricular failure. Described in this unit is an in vivo model of monocrotaline‐induced pulmonary hypertension in rats that can be used to assess the effects of antihypertensive agents on pulmonary artery pressure and right ventricular hypertrophy. Curr. Protoc. Pharmacol. 46:5.56.1‐5.56.11.
No takes yet. Share an insight, caveat, or question.
Rey et al. (2009) studied Pulmonary arterial hypertension. Monocrotaline was evaluated on Pulmonary artery pressure and right ventricular hypertrophy. Monocrotaline administration in Wistar rats provides an in vivo experimental protocol to evaluate antihypertensive agent effects on pulmonary artery pressure and right ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: